维普期刊资源整合服务平台（V6.5）

53篇 您的检索式：作者名="Mathijssen J"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Danusertib, an au- rora kinase inhibitor显示文摘	Meulenbeld HJ Mathijssen RH Verweij J	2012	Expert Opin Investig Drugs2012，21，3：	1
2	Irinotecan pharmacokinetics pharmacodynamicsthe clinical relevance of prolonged exposure to SN-38显示文摘	Mathijssen RHJ Verweij J Loos WJ	2002	Br J Cancer2002，87，：	1
3	Irinotecan pharmacokinetics-pharmacodynamics:the clinical relevance of prolonged exposure to SN-38显示文摘	Mathijssen RH Verweij J Loos WJ	2002	Br J Cancer2002，87，2：	1
4	Effects of St John's Wort on irinotecan metabolism 显示文摘	Mathijssen RHJ Verweij J De Bruijn P	2002	J Natl Cancer Inst2002，94，16：	1
5	Irinotecan phannacoki neties pharmaeodynamiesthe clinical relevance of prolonged 显示文摘	Mathijssen RHJ Verweij J Loos WJ	2002	Br J Cancer2002，87，：	1
6	Symptomatic Venous Thromhoemholism in Cancer Patients Treated with Chemotherapy: an Underestimated Phenomenon显示文摘	Otten H M Mathijssen J ten Cate H	2004	Arch Intern Med2004，164，2：	1
7	Symptomatic venous thromboembolism in cancer patients treated with chemotherapy:an underestimated phenomenon显示文摘	Otten HM Mathijssen J ten Cate H	2004	Arch Intern Med2004，164，2：	1
8	Clinical pharmacokinetics and metabolism of irinotecan( CPT-ll ) 显示文摘	MATHIJSSEN R H J van ALPHEN R J YERWEI J J et a1	2001	Clin Cancer Res2001，7，8：	1
9	The role of health technology assessment on pharmaceutical reimbursement in selected middle-in- come countries显示文摘	Oortwijn W Mathijssen J Banta D	2010	Health Policy2010，95，23：	1
10	Symptomatic venous throm- boembolism in cancer patientstreated with chemotherapy:an underesti- mated phenomenon显示文摘	Otten HM Mathijssen J ten Cate H	2004	Arch Intern Med2004，164，2：	1
11	Associations Between Environmental Characteristics and Active Commuting to School Among Children:A Cross-sectional Study显示文摘	Aarts M J Mathijssen J J P Oers J A M V	2013	International Society of Behavioral Medicine2013，20，4：	1
12	Moving towards dose individualization of tyrosine kinase inhibitors 显示文摘	KLUMPEN H J SAMER C F MATHIJSSEN R H	2011	Cancer Treat Rev2011，37，4：	1
13	Determining the best dose for the individual patient显示文摘	Mathijssen RH Loos WJ Verweij J	2011	J Clin Oncol2011，29，33：	1
14	Guidelines for reconstruction of the eyelids and canthal regions 显示文摘	Mathijssen I M van der Meulen J C	2010	J Plast Reconstr Aesthet Surg2010，63，9：	1
15	Clinical pharmaeokineties and metabolism of irinoteean (CPT-11)显示文摘	Ron HJ Mathijssen Robbert J van Alphen Jaap Verweij	2001	Clin Cane Res2001，7，8：	1
16	Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) 显示文摘	Mathijssen RH van Alphen R J Verweij J	2001	Clin Cancer Res2001，7，8：	1
17	Danusertib,an aurora kinase inhibitor显示文摘	Meulenbeld H.J Mathijssen R.H.J Verweij J		0，，03：	1
18	Guidelines for recon- struction of the eyelids and canthal regions 显示文摘	MATHIJSSEN I M Van Der MEULEN J C	2010	J Plast Reconstr Aesthet Surg2010，63，9：	1
19	Danusertib, an aurora kinase inhibitor 显示文摘	MEULENBELD H J MATHIJSSEN R H VERWEIJ J	2012	Expert Opin Investig Drugs2012，21，3：	1
20	Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon 显示文摘	Otten HM Mathijssen J ten Care H	2004	Arch Intern Med2004，164，2：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示